Flowserve Corporation Q3 2024 Earnings Call Transcript: A Professional, Educated, and Profit-Focused Analysis

Flowserve Corporation (NYSE:FLS) Q3 2024 Results Conference Call October 29, 2024 10:00 AM ET Company Participants Brian Ezzell – VP, IR, Treasurer and Corporate Finance Scott Rowe – President and Chief Executive Officer Amy Schwetz – Senior Vice President and Chief Financial Officer Conference Call Participants Andy Kaplowitz – Citigroup Nathan Jones – Stifel Deane…

Read More

Viking Therapeutics Releases Q3 2024 Financial Results and Corporate Update

Viking Therapeutics Announces Positive Financial Results and Clinical Pipeline Update Important Developments Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis…

Read More

Uncovering the Truth: Investors Accuse Farfetch Limited (FTCH) of Hiding Weak Demand in US and China – A Hagens Berman Investigation

Investors Allege Farfetch Limited (FTCH) Concealed Weak Demand in US, China – Hagens Berman HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FTCH Investors with Substantial Losses to Contact Firm’s Attorneys Before Dec. 19th Deadline in Securities Fraud Lawsuit SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges Farfetch Limited (NYSE: FTCH) investors who suffered…

Read More

Unlocking Profitability: Omega Therapeutics Unveils Groundbreaking Preclinical Data on Epigenomic Control of CXCL Genes

Omega Therapeutics Presents New Preclinical Data Demonstrating Coordinated Modulation of Epigenetic Profile CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — The latest research from Omega Therapeutics showcases the coordinated modulation of the epigenetic profile of CXCL1-8 genes, resulting in the downregulation of gene expression and protein levels. This modulation has been shown to inhibit immune…

Read More